Published on 11 May 2023 on Zacks via Yahoo Finance
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
Mirum Pharmaceuticals MIRM announced that the FDA has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in infants aged 3 months and older with Alagille syndrome (ALGS). Earlier, the drug was approved for patients aged 1 year and older. However, with this label expansion, the age of pediatric patients eligible for treatment with Livmarli has now been reduced from 1 year to 3 months. The stock of the company jumped 6.4% on Tuesday in response to the news.
In the past year, the shares of the company have risen 9.9% against the industry’s decline of 13.3%.
